Henocq E, Prouvost-Danon A, Bizzini B
Boll Ist Sieroter Milan. 1987;66(1):70-7.
Allergoids have been used successfully for immunotherapy of allergic disorders. It has appeared to us that the effect of allergoids could be potentiated by their coupling to an immunomodulator. In the present study we show that a conjugate made up of the coupling of ovalbumin through glutaraldehyde action to the C. granulosum-derived immunomodulator P40 is completely devoid of antigenicity and of cross-reactivity with ovalbumin. This conjugate was found to significantly inhibit mast cell degranulation. It also proved to be capable of protecting against the lethal systemic anaphylactic shock sensitized mice. Immunotherapy was performed in patients hypersensitive to either the pollen of Dactylis glomerata or to the house dustmite allergens using the conjugates made of the specific allergens and of the P40. Clinical improvement was observed in a significant percentage of the patients subjected to immunotherapy. Administration of the conjugates did not result in untoward reactions in any of the patients.
类变应原已成功用于过敏性疾病的免疫治疗。在我们看来,类变应原与免疫调节剂偶联后其效果可能会增强。在本研究中,我们表明通过戊二醛作用将卵清蛋白与颗粒丙酸杆菌衍生的免疫调节剂P40偶联而成的缀合物完全没有抗原性,也不与卵清蛋白发生交叉反应。发现该缀合物能显著抑制肥大细胞脱颗粒。它还被证明能够保护致敏小鼠免受致命的全身性过敏性休克。使用由特定变应原和P40制成的缀合物,对高草花粉或屋尘螨变应原过敏的患者进行了免疫治疗。在接受免疫治疗的患者中,有相当比例观察到临床改善。给患者注射缀合物未导致任何不良反应。